GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tharimmune Inc (NAS:THAR) » Definitions » Forward PE Ratio

Tharimmune (Tharimmune) Forward PE Ratio : 0.00 (As of Jun. 06, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Tharimmune Forward PE Ratio?

Tharimmune's Forward PE Ratio for today is 0.00.

Tharimmune's PE Ratio without NRI for today is 0.00.

Tharimmune's PE Ratio for today is 0.00.


Tharimmune Forward PE Ratio Historical Data

The historical data trend for Tharimmune's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tharimmune Forward PE Ratio Chart

Tharimmune Annual Data
Trend
Forward PE Ratio

Tharimmune Quarterly Data
Forward PE Ratio

Competitive Comparison of Tharimmune's Forward PE Ratio

For the Biotechnology subindustry, Tharimmune's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tharimmune's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tharimmune's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Tharimmune's Forward PE Ratio falls into.



Tharimmune Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Tharimmune  (NAS:THAR) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Tharimmune Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Tharimmune's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Tharimmune (Tharimmune) Business Description

Traded in Other Exchanges
N/A
Address
1200 Route 22 East, Suite 2000, Bridgewater, NJ, USA, 08807
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting unique epitopes with novel mechanisms of action against well-known, validated targets in multiple solid tumors.
Executives
Randy Milby director, officer: Chief Executive Officer 5 JACK LANE, NEWARK DE 19711
Kelly Anderson director C/O TOMI ENVIRONMENTAL SOLUTIONS, INC., 9454 WILSHIRE BLVD., R-1, BEVERLY HILLS CA 90212
Leonard L Mazur director C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD NJ 07016
Sandeep Laumas 10 percent owner 8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
Thomas Hess officer: Chief Financial Officer 366 MADISON AVE. 12TH FLOOR, NEW YORK NY 10017
Sireesh Appajosyula director 1200 ROUTE 22 EAST, SUITE 2000, BRIDGEWATER NJ 08807
Lynne A. Bui director 1200 ROUTE 22 EAST, SUITE 2000, BRIDGEWATER NJ 08807
Surender Kharbanda 10 percent owner 1200 ROUTE 22 EAST, SUITE 2000, BRIDGEWATER NJ 08807
Highpoint Pharmaceuticals Llc 10 percent owner 16192 COASTAL HIGHWAY, LEWES DE 19958
Kufe Llc 10 percent owner 179 GROVE STREET, WELLESLEY MA 02482
Varinder Kaur 10 percent owner 1200 ROUTE 22 EAST, SUITE 2000, BRIDGEWATER NJ 08807

Tharimmune (Tharimmune) Headlines

From GuruFocus

Hillstream BioPharma Announces Proposed Public Offering

By sperokesalga sperokesalga 04-27-2023

Hillstream BioPharma Announces Pricing of Public Offering

By GlobeNewswire GlobeNewswire 04-28-2023